---
title: "STRATA CRITICAL MED INC C/WTS 07/05/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 49.3 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265144471.md"
datetime: "2025-11-10T12:08:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265144471.md)
  - [en](https://longbridge.com/en/news/265144471.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265144471.md)
generator: "portal-rs"
---

# STRATA CRITICAL MED INC C/WTS 07/05/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 49.3 M

Revenue: As of FY2025 Q3, the actual value is USD 49.3 M.

EPS: As of FY2025 Q3, the actual value is USD -0.12.

EBIT: As of FY2025 Q3, the actual value is USD -6.749 M.

### Financial Metrics by Segment

#### Segment Revenue

-   Total revenue for Q3 2025 was $49.3 million, a 36.7% increase from $36.1 million in Q3 2024. Excluding the Keystone acquisition, revenue increased by 29.0%.

#### Operational Metrics

-   Net loss from continuing operations increased to - $9.7 million in Q3 2025 from - $5.6 million in Q3 2024, primarily due to a $5.2 million increase in realized loss from sales of short-term investments and a legal reserve.
-   Gross profit for Q3 2025 was $9.5 million, up 75.9% from $5.4 million in Q3 2024. The gross margin improved to 19.4% from 15.0% in the prior year period.
-   Adjusted EBITDA increased to $4.2 million in Q3 2025 from $0.1 million in Q3 2024, marking a significant improvement.
-   Medical Segment Adjusted EBITDA rose by 93.5% to $7.6 million in Q3 2025, with the margin increasing to 15.3% from 10.8% in Q3 2024.

#### Cash Flow

-   Operating cash flow was - $37.3 million in Q3 2025, impacted by $44.3 million of Keystone acquisition consideration included in operating cash flow.
-   Free cash flow from continuing operations was $1.9 million in Q3 2025, excluding acquisition consideration and transaction costs.

#### Unique Metrics

-   No unique company-specific financial indicators were mentioned in the reference.

#### Outlook / Guidance

-   Strata Critical Medical raised its 2025 revenue guidance to $185-195 million and reaffirmed its Adjusted EBITDA guidance of $13-14 million.

### Related Stocks

- [SRTAW.US](https://longbridge.com/en/quote/SRTAW.US.md)

## Related News & Research

- [Inside Coca-Cola’s secretive innovation labs: How the beverage giant wants to automate dirty soda and refreshers](https://longbridge.com/en/news/296681725.md)
- [Emerald Investment Advisers LLC Makes New Investment in OGE Energy Corporation $OGE](https://longbridge.com/en/news/296677287.md)
- [Callan Family Office LLC Acquires Shares of 20,279 Installed Building Products, Inc. $IBP](https://longbridge.com/en/news/296677126.md)
- [Deutsche Bank AG Acquires Shares of 401,562 Viasat Inc. $VSAT](https://longbridge.com/en/news/296676399.md)
- [Bank of America Corp DE Acquires 173,486 Shares of Trustmark Corporation $TRMK](https://longbridge.com/en/news/296675221.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**